Our News

Biofilm:

The Infection Threat Many Have Never Heard Of

Click above to watch Mark Hodgson from Medentech, part of the Kersia group and George Clarke, founder and CEO of the UMF Corporation discuss COVID-19, biofilm and how to combat it.

 

In this special HAI (Healthcare Associated Infection) podcast hosted by Tyler Kern, Mark Hodgson from Medentech, part of the Kersia group and George Clarke, founder and CEO of the UMF Corporation discuss how the COVID-19 pandemic has caused a crash course in infection prevention protocols.

Listen as they deep dive into the standard infection protection protocols established prior to COVID-19 and the updated infection prevention procedures to combat the new infection threat that many of you have yet to hear about - BIOFILM

BIOFILM – is a naturally occurring complex matrix, which can include bacteria, viruses and fungi. Biofilms allow pathogens to adhere to a solid surface and be enveloped and protected. The biofilm protects microorganisms from many disinfectant products, which means, it is essential to use the correct infection prevention disinfectant that is EPA proven effective against biofilm.

Learn about the critical importance of environmental hygiene that could reduce hospital-associated infections that exceeded 1 million infections since the 1990s with an estimated 100,000 deaths every year.

Key Takeaway Points:

• The world of infection prevention changed during the pandemic.

• Hospitals had to rethink their strategy on how to combat infections.

• Pre-Covid, healthcare admin worried about C.diff, Staph, and MRSA

 

Did you know that our NaDCC disinfection tablets are approved by the US EPA as effective against biofilm? In 2018 The US EPA approved Klorkleen 2 (71847-7), the first hospital grade disinfectant product to be effective against these biofilms.

 


SARS-CoV-2 / Coronavirus
Clostridioides difficile
Bacteria methicillin-resistant Staphylococcus aureus
Antibiotic resistant bacteria inside a biofilm

Ebola

Protection & Procedures during an outbreak

Ebola Virus Disease (EVD) is a rare and deadly zoonotic disease that affects humans, monkeys, gorillas and chimpanzees It was discovered in 1976 and occasionally infects people leading to outbreaks that can spread through direct contact with bodily fluids of an infected person or objects that are contaminated by them.

This spillover event happens when a human is initially infected through contact with an infected animal such as a fruit bat or non human primate. The virus can thereafter spread from person to person, with the potential to affect large numbers of people.

Key Fact:

A person can only spread Ebola to other people after they develop signs and symptoms of Ebola. Check out the app that estimates when a person with Ebola was exposed to the virus.

www.cdc.gov/vhf/ebola/transmission/index.html

Ebola Fact: You can’t get Ebola through air / Water or Food

HOW DOES EBOLA SPREAD?

When initial exposure to the virus occurs, people do not immediately develop symptoms straight

away. An incubation period has been observed by scientists prior to the disease becoming active and when a person is contagious. Only when a person develops signs and symptoms of Ebola, can they spread the virus to others. The symptoms are headache, joint and muscle aches, weakness, diarrhoea, vomiting, rash, red eyes, stomach pain, lack of appetite, and in some cases, bleeding. The virus spreads through direct contact with broken skin, through mucous membranes in the eyes nose and mouth. Examples of direct contamination are:

• Blood or bodily fluids (saliva, sweat, urine, faeces, breast milk amniotic fluid) of an infected person or someone who has died from EVD.

• Infected fruit bats or non-human primates.

• EVD can remain in certain body fluids of a patient who has recovered, even when they no longer have symptoms.

For key facts from the World Health Organisation on Ebola virus disease click here: www.who.int/news-room/fact-sheets/detail/ebola-virus-disease

“Ebola threatens everything that makes us human” WHO

DID YOU KNOW?

3-4% of infected patients are health Care Workers!

During an outbreak, healthcare facilities should maintain a log of all persons entering the facility. Consistent standard practices are essential when caring for infected patients, healthcare

workers should:

• Wear protective clothing - to include masks, gloves, gowns and eye protection.

• Double glove if heavy duty gloves not available.

REMEMBER! The use of gloves does not replace the need for cleaning your hands!

• Isolate patients with Ebola from other patients

• Avoid direct contact with bodies of those who have died from Ebola..

• When de-robing ensure exposed surfaces do not come in contact with your body. Roll gowns in on

themselves.

Healthcare providers should frequently perform hand hygiene before and after:

• All patient contact.

• Contact with potentially infectious material

• Before putting on and upon removal of PPE - to include gloves.

 

Find a report form the World Health Organisation on the impact of Ebola on health workforce of Guinea, Liberia and Sierra Leone here: www.who.int/publications/i/item/WHO-EVD-SDS-REPORT-2015.1

EBOLA Patient Room Infection Control

• Dedicated medical equipment ( preferably disposable, when possible) should be used for provision of patient care.

• All non-dedicated, non-disposable medical equipment used for patient care should be cleaned and disinfected with Klorkleen @1000ppm.

Find detailed information on personal protective equipment from the World Health Organisation here: www.who.int/publications/i/item/WHO-EVD-Guidance-PPE-14.1

Procedure:

First clean the room with Klorkleen @1000ppm

• Then disinfect with fresh batch of Klorkleen solution @1000ppm

• Work from area furthest from the patient first, towards the patient (or bed)

• Ensure surface being disinfected is thoroughly wet, ideally the surface should be wet for 5 minutes

• Dispose of all used paper towels and cloths by incineration where possible.

Where cloths cannot be disposed of effectively, soak in a 1000ppm solution for 1 hour before separated laundry procedure.

Standard safety work practices combined with a robust infection prevention cleaning procedure, will help to control the infection within the facility and protect healthcare workers as they strive to save the lives of their patients.

Ebola

Wash Your Hands!

Click here for the correct hand washing procedure
Klorkleen, the 2in1 product that disinfects and cleans

Aquatabs WASH KIT

Click here to view all the disinfection requirements for a rural healthcare facility for 1 year in a box! That's infection prevention for all surfaces, medical instruments, all water & hand disinfection. 
Simple to use, easy to store, effective infection prevention.
Klorsept, a range of high level, broad spectrum disinfectants for hospitals and healthcare facilities. Or anywhere infection control is a priority!

EPA approve

Kersia Disinfectant Tablets with Electrostatic Sprayers

Another EPA Approval For NaDCC Disinfectant Tablets

November 4th, 2021

 

As a global leader in infection prevention products and solutions, we are very happy to announce the approval of an electrostatic spray application claim for use with our NaDCC disinfectant tablets. This EPA (United States Environmental Protection Agency) approval has expanded the claims for KLORSEPT (EPA Reg No. 71847-6) and KLORKLEEN 2 (EPA Reg No: 71847-7) with the addition of the electrostatic spray application to the labels.

“When you use our tablets there is no need to wait before one reoccupies a room, unlike other chemistries.” Michael Gately CEO, Medentech

Our mission is clear, assist our customers to create a safe environment that protects employees and customers alike. Protection from exposure risks connected to COVID-19 and other pathogens such as Candida Auris, C. diff, including surface biofilms.

 

"Our US EPA approved NaDCC disinfectant tablets have been the preferred chemistry with electrostatic sprayers based on their optimal efficacy, safety, sustainability, and ease of use. Simply fill the electrostatic sprayers with tap water and drop in a tablet. When you use our tablet (s) there is no need to wait before one reoccupies a room, unlike other chemistries.” Michael Gately CEO, Medentech.

We manufacture a range of high-level broad-spectrum NaDCC disinfectant tablets that are used in hospitals globally
With our US EPA approved products there's no need to wait before one reoccupies a room, unlike other chemistries

MARBURG VIRUS

WHAT IT IS AND INFECTION PREVENTION MEASURES

Marburg virus disease (MVD) is a severe, often fatal illness in humans, causing severe haemorrhagic fever. MVD is caused by the Marburg virus, an RNA virus of the filovirus family (other members include the six Ebola virus species). The virus is transmitted to people from fruit bats and spreads among humans through human-to-human transmission.

 

The transmission can be via direct contact (through broken skin or mucous membranes) with the blood, secretions or other bodily fluids of infected people, and also with surfaces and materials (e.g. bedding, clothing) contaminated with these fluids.

 

An outbreak of Marburg virus has been reported recently in Guinea.

EFFICACY OF KLORSEPT & KLORKLEEN AGAINST MARBURG VIRUS

Infection prevention measures will be key in the prevention of the spread of this virus. EN14476:2013+A1:2015 is a European test standard that evaluates the virucidal efficacy of disinfectants via testing of Poliovirus Type 1, Adenovirus Type 5 and Murine Norovirus.

 

In accordance with EN14476:2013+A1:2015, Annex A, Medentechs products Klorsept, Aquatabs and Klorkleen have full virucidal activity when used as surface disinfectants. Meaning they are effective against the Marburg virus.

 

These products are effective when used at 500 ppm when surfaces have been pre-cleaned and at 1000 ppm when used under dirty conditions. A 5 minute contact time is required.

Klorsept - full virucidal activity against MVD when used as a surface disinfectant
Rousettus aegyptiacus, fruit bats of the Pteropodidae family, are considered to be natural hosts of Marburg virus.
Klorkleen - full virucidal activity against MVD when used as a surface disinfectant.
Aquatabs - full virucidal against MVD activity when used as a surface disinfectant

Prioritising WASH To Save Lives

In 2019, resolution WHA72.7 on WASH (water, sanitation and hygiene) in healthcare facilities was adopted by the World Health Assembly. The aim:- by 2025, increase the number of healthcare facilities with basic WASH facilities by 80% moving to 100% by 2030 apps.who.int/gb/ebwha/pdf_files/WHA72/A72_R7-en.pdf

The reality is that one in ten healthcare facilities globally do not have sanitation services and one in four, no basic water supply. In LDCs (least developed countries ) the problem is worse, half of the facilities lack basic water with up to 60% lacking sanitation services. COVID-19 has decimated the well meaning plans by many countries to maintain their commitment to sustainable development goal 3: (Ensure healthy lives and promote health and well-being for all at all ages) and Goal 6 (Ensure availability and sustainable management of water and sanitation for all)

However, WASH is not just about sustainable goals. It is about dignity, it's about servicing the needs of patients, it's ensuring that healthcare workers feel safe while at work, it’s about saving the lives of the many women and babies who die during childbirth for lack of basic hygiene services.

- Women need clean healthcare facilities at one of the most critical times in their lives

- They want water and soap to wash and take care of their newborns

- They want an environment that is safe from infection for their baby and their own recuperation.

Buying into WASH could reduce by half the global death rate of sepsis associated healthcare cases of which there are approx 11 million a year

Financial support is critical

WASH is a “best buy” according to the OECD (Organisation for Economic Co-operation and Development) Promoting hand hygiene and investing in better hospital hygiene have the potential to pay for themselves within a year It’s time to invest in solutions that are accessible, cost effective and sustainable, WASH must be at the highest level of global budgetary requirements and remain there for universal health to prosper.

National governments, organisations, communities and the commercial sector can move affordable

WASH in healthcare forward together by supporting lasting infrastructure.

Blended finance is one way to take the risk out of funding healthcare and scale up investment in LDCs. Combining innovative, sustainable models that can be adjusted to local requirements open opportunities and supports sustainable development.

Aquatabs continue to deliver sustainable water purification systems for schools and communities, 40 million children access safe drinking water everyday in Kenya and Nigeria.

 

Aquatabs Year In A Box has been designed to bring low cost infection prevention to small communities and healthcare facilities while supporting social enterprises engaged in improving access to WASH services in developing economies.

With the Aquatabs Year In A Box (YIAB) mix and match system, you receive your exact requirement for the year:

All water requirements

All surface disinfection needs

All instrument disinfection needs

All handwashing requirements

Contact us today to find out how our experts can help you with personalised infection prevention training and facility needs.


Food Insecurities – A worldwide Crisis

The 2021 global report on food crises has shown the worsening of food insecurity worldwide. Of the 55 countries highlighted with food crises, 10 countries are in crisis where households have high or above average acute malnutrition and require urgent supplies.

The main factors that exacerbate food insecurity have not changed. Prolonged conflict in many areas delay emergency operations in the field, hindering supply to critically vulnerable communities. Ongoing weather extremes such as heavy rains, severe flooding and tropical storms throughout 2020 took away the livelihoods of those affected and caused ecological devastation in parts of Africa, South Asia, Central America and the Middle East. Add to the above the economic downturn following COVID-19, the worst since World War II, and we just begin to understand the nightmare that over 155 million people are experiencing. Read the full report here: www.wfp.org/publications/global-report-food-crises-2021

In the midst of all this are children who are facing severe acute malnutrition.

In 2020 15.8 million children under the age of 5 years old were suffering from wasting, half of those live in the 10 countries found to be in phase 3 or above on the integrated food security classification (IPC). Phase 3 classifies as “households experiencing food consumption gaps with high or above usual acute malnutrition / accelerated depletion of livelihood assets / resort to crisis coping strategies”

1st 1000 days

The first two years of a child’s life, also known as the first 1000 days, are critical for cognisance. Malnutrition damages a child’s cognitive and physical development, it is mostly irreversible and leads to illness, severely depletes the quality of a child’s life and leads to inequalities in adult life.

A baby’s world revolves around the love, protection and nutrition mother provides. Good maternal health is essential for a healthy baby, yet breastfeeding women are projected to continue being acutely malnourished in 2021.

 

“Diseases and a poor health environment are key drivers of childhood malnutrition”

WHO Director-General Dr Tedros Adhanom Ghebreyesus

Children who are malnourished are further susceptible to, and have a higher burden to debilitating water borne disease such as cholera and giardia. Limiting access to safe drinking water and RUTF (ready-to-use therapeutic food) significantly reduces their chances of survival. In the following link you will find a publication that demonstrates the impact of a WASH intervention in the management of severe acute malnutrition. In brief, the main robust conclusions were:

Point-of-use water treatment improves recovery rates among children with severe acute malnutrition in Pakistan : results from a site-randomized trial:

Recovery rates 16.7- 22.2% higher among children receiving water treatment

• The intervention decreased the time-to-recovery (4.4 days; P = 0.038),

• It improved the recovery rate (10.5%; P = 0.034),

• It increased the absolute weight gain (3.0 g/d; P = 0.014).

 

Find the full report here: pubmed.ncbi.nlm.nih.gov/29488461/

 

We are very much focused on playing our part, whether it be delivering

- SUSTAINABLE WASH water purification systems for schools and rural communities.

- Providing high quality affordable WASH’NUTRITION essential water and nutritional products.

- WASH in HEALTHCARE effective infection prevention solutions for water, surface, instruments and hands in hospitals and small communities

 

Contact us to find out more about our activities in creating social enterprises, bringing sustainable solutions to healthcare, making water safe and nutrition accessible in the most challenging circumstances: [email protected]

Aquatabs effervescent tablets are used in emergency situations to disinfect water from 1L to 2,500L
WASH'NUTRITION
Mix and match packs: Ready-to-use therapeutic foods, Aquatabs for water disinfection and
Klorkleen for cleaning and disinfecting surfaces.
WASH in HEALTHCARE:
Aquatabs Year In A Box (YIAB) Low cost mix and match disinfection products for rural healthcare centres and hospitals. Aquatabs Flo and Aquatabs InLine for disinfection of large volumes of water - Klorkleen for surface disinfection - Ultraseptin for sterilisation of endoscopes and medical instruments.

Coronavirus (2019-nCoV)

WHO recommends NaDCC Granules

5th February 2020

 

The 2019 novel coronavirus (2019-nCoV) outbreak is continuing to evolve with many cases having now been detected outside of Wuhan, China. As of February 4th, the World Health Organisation (WHO) have reported 425 deaths in China and 20,630 confirmed cases globally. A total of 159 cases have been identified outside of China, spread worldwide across 23 countries. There has been one recorded death outside of China.

 

As a result, the WHO have declared the 2019-nCoV outbreak a public health emergency of international concern (PHEIC). By declaring this outbreak a PHEIC, the WHO has highlighted the urgency and need for international efforts to minimize further spread. The aim of a PHEIC is to ensure a global response that is evidence-based, measured and balanced. The enhanced cooperation will increase transparency, the development of vaccines, diagnostics and therapeutics. For more information on the WHO’s response, please visit:

www.euro.who.int/en/health-topics/emergencies/pages/news/news/2020/01/2019-ncov-outbreak-is-an-emergency-of-international-concern

 

Although the WHO is still to determine the survival capabilities of 2019-nCoV on surfaces, preliminary information suggests the virus could survive for several hours. In the case of high touch surfaces which could harbour respiratory droplets from an infected patient, regular disinfection is necessary. Our surface disinfectant products are effective at killing this viral pathogen. The WHO have also recommended the use of NaDCC granules for the disinfection of healthcare facilities as part of their recommended Disease commodity package – Novel Coronavirus

 

www.who.int/publications-detail/disease-commodity-package---novel-coronavirus-(ncov)

 

 

C​andida auris

An Unusual Yeast Causing Serious Infection

C​andida auris – An Unusual Yeast Causing Serious Infection

 

 

Over the past number of years discussion surrounding Candida auris has continued to increase. This pathogen is regularly discussed by the media and governmental bodies. It is of high concern to healthcare facilities. But what is Candida auris and why is it gaining so much attention?

 

Candida auris is a fungal pathogen, to be more specific, it is a type of yeast. This pathogen was first reported in Japan in 2009 and has since been linked with healthcare associated infections (HAIs) on five continents (1). C. auris control is challenging due to the difficulty in identifying this pathogen in the clinical laboratory. Moreover, C. auris often exhibits high levels of multi drug resistance, leading to high rates of treatment failure with invasive infections (2). The United States Centers for Disease Control and Prevention (CDC) map new case reports worldwide (https://www.cdc.gov/fungal/candida-auris/tracking-c-auris.html).

 

As of January 31st, 2019, a total of 560 confirmed clinical cases have been identified in the U.S.

The most commonly observed invasive infection associated with C. auris has been blood stream infections, with mortality in the range of 30 to 60%. Patients involved generally have high healthcare exposure, however, infection may not be apparent until weeks after initial admission (2). The best treatment practice for C. auris infection has not been defined.

C. auris appears to spread via patients and the environment. It has be isolated from the skin of affected patients as well a patient contact areas, such as sinks, medical equipment, furniture and mattresses (3, 4). Recent investigations suggest quaternary ammonium compounds may not be effective against C. auris (5). The US CDC recommend that sporicidal disinfectants (those listed on the U.S. EPA List K) be used where C. auris is of concern and provide several other points of interest in relation to C. auris transmission control, such as hand hygiene and contact precautions (https://www.cdc.gov/fungal/candida-auris/c-auris-infection-control.html).

 

There is still a lot to learn regarding this pathogen, such as its origin in the natural environment, the reason for its sudden emergence and high antifungal resistance. Healthcare workers should remain ever vigilant for C. auris where Candida spp. infection is suspected due to its impact on patient mortality. Undoubtedly control of these outbreaks will prove a challenge until more information about this unusual pathogen become available. Providing care in accordance with best practice outlined by the CDC will be key until more defined control mechanisms become apparent.

 

 

1. Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H. 2009. Candida auris sp . nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol. Immunol: 53:41–44

2. Spivak ES, Hanson E. 2018. Candida auris : an Emerging Fungal Pathogen. J. Clin. Microbiol. 56:1–10.

3. Vallabhaneni S, Kallen A, Tsay S, Chow N, Welsh R, Kerins J, Kemble SK, Pacilli M, Black SR, Landon E, Ridgway J,Palmore TN, Zelzany A, Adams EH,Quinn M, Chaturvedi, S, Greenko J, Fernandez R, Southwick K, Furuya EY, Calfee DP, Hamula C, Patel G, Barrett P, Lafaro P, Berkow EL, Moulton-Meissner H, Noble-Wang J,Fagan RP, Jackson BR, Lockhart SR, Litvintseva AP, Chiller TM. 2017. Investigation of the First Seven Reported Cases of Candida auris , a Globally Emerging Invasive Multidrug-Resistant Fungus — United States , May 2013 – August 2016. Amer. J. Transplant. 17:296-299

4.Schelenz S, Hagen F, Rhodes JL, Abdolrasouli A, Chowdhary A, Hall A, Ryan L, Shackleton J, Trimlett R, Meis JF, Armstrong-james D, Fisher MC. 2016. First hospital outbreak of the globally emerging Candida auris in a European hospital. Antimicrob Resist Infect Control. 5:35.

5. Cadnum JL, Shaikh AA, Christina T, Sankar T, Jencson AL, Larkin EL, Ghannoum MA, Donskey CJ. 2017. Effectiveness of Disinfectants Against Candida auris and Other Candida Species. Infect. Control and Hosp. Emidemiol. 38:1–4.

 

 

Kersia Coronavirus Update